accessible
132 results
1 - 100
Differences in U.S. and Canadian Pharmaceutical Practices- alteplase
- reteplase
- remdesivir
- urokinase
- Controlled Substances Schedules
- cerliponase alfa
- eptifibatide
- retapamulin
- ibritumomab
- tirofiban
- peginesatide
- molnupiravir
- C1-esterase inhibitor, recombinant
- magnesium sulfate (parenteral)
- calcipotriene
- daprodustat
- echinacea
- nesiritide
- epoprostenol
- coagulation factor XIII A-subunit (recombinant)
- alemtuzumab
- sipuleucel
- Detecting and Managing Adverse Drug Reactions
- remifentanil
- vigabatrin
- rocuronium
- eteplirsen
- opioid analgesics
- bivalirudin
- loxapine
- cisatracurium
- vecuronium
- chlorpheniramine polistirex/codeine polistirex
- Evidence-based Practice and Pharmacotherapeutics
- atracurium
- adenosine
- succinylcholine
- FENTANYL (transmucosal)
- central nervous system stimulants
- guaiFENesin
- pancuronium
- ibalizumab
- solriamfetol
- abciximab
- NEUROMUSCULAR BLOCKING AGENTS (nondepolarizing)
- Davis’s Drug Guide for Nurses
- enoxaparin
- treprostinil
- fentaNYL (transdermal)
- tenecteplase
- butorphanol
- estazolam
- carisoprodol
- modafinil
- ocrelizumab
- argatroban
- chlordiazePOXIDE
- darbepoetin
- flurazepam
- lutetium lu 177 dotatate
- lipid emulsion, injectable
- daratumumab
- levETIRAcetam
- levorphanol
- nalbuphine
- teniposide
- SUFentanil
- methoxy polyethylene glycol-epoetin beta
- ravulizumab
- oliceridine
- lenacapavir
- cloBAZam
- trilaciclib
- daridorexant
- buprenorphine
- codeine
- diazePAM
- buprenorphine/naloxone
- Overview of Risk Evaluation and Mitigation Systems (REMS)
- lasmiditan
- epoetin alfa
- ALPRAZolam
- LORazepam
- oxazepam
- sodium oxybate